ATTO / EXCLUDED

Attovia Therapeutics, Inc.

GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS GROUP INC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS OFFSHORE INVESTMENTS, SLP; WSLS EMP ONSHORE INVESTMENTS, L.P.
Other; Other; Other; Other; Other; Other; Other; Other

Common Stock · Transaction 2026-08-05 · Filed 2026-08-28

Original SEC filing · Accession 0000886982-26-000522 · Row 9058036

Reported transaction details

Shares transacted: 447.0
Security / share class: Common Stock
Reported ownership: Indirect — see ownership footnotes
Reported price per share: 21.87
Transaction value (shares × reported price): 9,775.89

Uses reconciled original-filing precision. Value is derived and may be approximate when the filing reports rounded or averaged prices. Currency has not been independently verified. These are reported transaction amounts, not adjusted market prices used for returns.

Historical purchase-size comparison is not yet available. The pilot does not establish this insider’s usual purchase size.

Excluded: not a qualifying purchase

The current analysis covers qualifying purchases of U.S.-listed ordinary/common shares and excludes funds and preferred shares.

Returns were not calculated for this transaction. This does not mean zero performance or missing price data. The reported amounts and original filing remain available for reference.

Assessment

Recorded assessment reasons

amendment review
not purchase acquisition
no executive or director
joint owner review
beneficial owner attribution review
historical security identity unverified

Original filing: reconciled. Security: review.

Reported bulk amounts: 447.0 shares × 21.87 per share.

Referenced filing footnotes

These transactions in or with respect to the common stock of the Issuer were effected by Goldman Sachs & Co. LLC ("GS&Co") acting as a market maker in the ordinary course of business. Without conceding market making trades in the ordinary course of business can result in liability under Section 16(b) of the Exchange Act, the amount of profit potentially recoverable by the Issuer from the reported transactions in the event that they were subject to Section 16(b) will be remitted to the Issuer.

Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that any such Reporting Person is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

GS&Co's transactions in or with respect to the Issuer's common stock on August 5, 2026 consisted of purchases of a total of 85,000 shares, sales of a total of 105,807 shares, and establishment of long equity swap positions with respect to a total of 105,807 shares. The equity swap positions were inadvertently omitted from the Reporting Persons' original Form 4.

Method and limitations

Daily-close v1: split-adjusted SIP daily bars supply purchase-date closes and all exit closes for both stock and SPY. Disclosure entries use each symbol's first regular-session minute open strictly after SEC acceptance + five minutes; acceptance is a publication proxy. Entry is session zero; exits occur at i+h. Daily bars are used only after the New York calendar day has ended, with a 15-minute data delay. Prices are vendor aggregates, not guaranteed fills or universally identical to official auction prices. Excludes dividends, fees and slippage. Related transaction rows are not independent signals.

Run cutoff: 2026-11-04T12:55:26.004Z. SEC acceptance: 2026-08-28T21:38:09.000Z.

Discretionary intent remains uncertain unless supported by the filing. Unresolved amendments and security identities are not silently treated as eligible trades.